Study Comparing Staying on Dolutegravir or Switching to Ritonavir-boosted Darunavir for Managing Dolutegravir Resistance in People Living with HIV
Led by University of Nairobi · Updated on 2025-09-11
392
Participants Needed
9
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the management of drug resistance in people living with HIV who are on dolutegravir DTG-based antiretroviral therapy but experience treatment failure due to drug-resistant mutations. This phase 3b randomized clinical trial aims to compare the effectiveness and safety of continuing DTG versus switching to ritonavir-boosted darunavir DRVr in patients with HIV-1 RNA levels above 200 copiesmL and at least one major DTG-associated drug resistance mutation. The study addresses gaps in current treatment strategies across several countries.
Participants will be randomly assigned to one of two groups one will continue their existing DTG-based ART regimen, and the other will switch to a DRVr-based ART regimen. The dosing will be based on weight, and the study will take place over 12 months at multiple sites in Kenya, Mozambique, Tanzania, and Lesotho. The primary measure is the proportion of participants achieving viral suppression with HIV-1 RNA below 200 copiesmL at 6 months.
During the trial, participants will have regular monitoring of their viral load and drug resistance mutations, along with assessments of treatment adherence, safety, and patient satisfaction. Additional outcomes include viral suppression rates at 12 months, incidence of adverse events, and changes in CD4 counts. The study includes children aged 3 years and older and plans to enroll 392 participants. Follow-up and data collection will support understanding optimal treatment management for this population.
CONDITIONS
Brief Title
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
Research Team
J
Joseph Nkuranga, MBChB, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Able and willing to understand and comply with protocol requirements
Able and willing to provide informed consent (and assent if appropriate)
Age 3 years or older
Most recent HIV-1 RNA of 200 copies/mL or higher
At least one major dolutegravir-associated drug resistance mutation (specific codons listed)
You will not qualify if you...
Pregnant or breastfeeding
Using any disallowed concomitant therapy with study drugs
WHO stage 3 or 4 opportunistic infection within 4 weeks prior to screening
Investigator opinion that participant should discontinue dolutegravir immediately
Investigator opinion that participant should not switch to ritonavir-boosted darunavir for clinical reasons
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 months
Participants are randomly assigned to either continue their dolutegravir-based ART regimen or switch to a ritonavir-boosted darunavir-based ART regimen. Treatment duration covers active medication use and monitoring.
Regular visits for treatment monitoring and assessments over 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 2 Study Comparing Injectable GS-3242 Plus Lenacapavir Versus Oral Biktarvy in Adults With Suppressed HIV-1
Open-label Study for Continued Access to Gilead HIV Treatments in Children and Adolescents Who Completed Parent Clinical Studies
Evaluating Acceptance and Commitment Therapy Compared to Brief Intervention for Reducing Unhealthy Drinking in Adults with HIV
Overcoming Barriers to Preventing and Treating Cardiometabolic Disorders
in People Living With HIV in the Southeastern United States
Study of Venetoclax to Promote Death of HIV-infected Cells and Reduce HIV Reservoir Size in People Living With HIV on Antiretroviral Therapy
Evaluating Caspofungin Treatment for Pneumocystis Pneumonia in Adults with HIVAIDS
Comparing Caspofungin with Standard TrimethoprimSulfamethoxazole Therapy
Evaluating the Safety and Effectiveness of DolutegravirLamivudine Compared to Other Regimens in Pregnant Women with HIV-1
Phase III Trial Comparing Doravirine and Dolutegravir-based Treatments for People Living with HIV-1 Who Have Never Received Antiretroviral Therapy
Comparing DoravirineLamivudine and DolutegravirLamivudine Dual Therapies to Maintain Viral Control in Adults Living with HIV-1 on Stable Triple Therapy
Evaluating Doravirine Combined Therapy for Rapid Start of HIV-1 Treatment in Adults Without Prior Antiretroviral Use
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol.
Loice Achieng Ombajo, Joseph Nkuranga, Jeremy Penner...